Skip to main content

Remote Job Finders (RJF)

J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.

Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.
Scroll to top